Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Express Scripts
McKinsey
Boehringer Ingelheim
Colorcon
AstraZeneca
Chinese Patent Office
US Army
Teva

Generated: December 14, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ZYPREXA ZYDIS

« Back to Dashboard

Clinical Trials for Zyprexa Zydis

Trial ID Title Status Sponsor Phase Summary
NCT00000374 Treatment for First-Episode Schizophrenia Completed National Institute of Mental Health (NIMH) Phase 4 This 3-year study will determine if the antipsychotic medications olanzapine (Zyprexa®) and risperidone (Risperdal®) can help patients with first-episode schizophrenia.
NCT00000374 Treatment for First-Episode Schizophrenia Completed The Zucker Hillside Hospital Phase 4 This 3-year study will determine if the antipsychotic medications olanzapine (Zyprexa®) and risperidone (Risperdal®) can help patients with first-episode schizophrenia.
NCT00000374 Treatment for First-Episode Schizophrenia Completed Northwell Health Phase 4 This 3-year study will determine if the antipsychotic medications olanzapine (Zyprexa®) and risperidone (Risperdal®) can help patients with first-episode schizophrenia.
NCT00044655 Switching Medication to Treat Schizophrenia Completed National Institute of Mental Health (NIMH) Phase 4 This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia.
NCT00044655 Switching Medication to Treat Schizophrenia Completed Icahn School of Medicine at Mount Sinai Phase 4 This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia.
NCT00048802 Treatment and Outcome of Early Onset Bipolar Disorder Completed National Institute of Mental Health (NIMH) Phase 4 This study will compare the effectiveness in the maintenance of continuing adjunctive atypical antipsychotic medication compared to traditional mood stabilizer(s) alone in the maintenance treatment of adolescents with bipolar disorder.
NCT00048802 Treatment and Outcome of Early Onset Bipolar Disorder Completed Northwell Health Phase 4 This study will compare the effectiveness in the maintenance of continuing adjunctive atypical antipsychotic medication compared to traditional mood stabilizer(s) alone in the maintenance treatment of adolescents with bipolar disorder.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Zyprexa Zydis

Condition Name

Condition Name for Zyprexa Zydis
Intervention Trials
Schizophrenia 19
Schizoaffective Disorder 8
Bipolar Disorder 7
Healthy 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Zyprexa Zydis
Intervention Trials
Schizophrenia 19
Psychotic Disorders 9
Disease 9
Bipolar Disorder 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Zyprexa Zydis

Trials by Country

Trials by Country for Zyprexa Zydis
Location Trials
United States 84
Canada 7
India 6
Spain 5
Italy 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Zyprexa Zydis
Location Trials
New York 11
California 7
Illinois 6
Georgia 5
Ohio 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Zyprexa Zydis

Clinical Trial Phase

Clinical Trial Phase for Zyprexa Zydis
Clinical Trial Phase Trials
Phase 4 16
Phase 3 5
Phase 2/Phase 3 2
[disabled in preview] 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Zyprexa Zydis
Clinical Trial Phase Trials
Completed 34
Terminated 5
Recruiting 3
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Zyprexa Zydis

Sponsor Name

Sponsor Name for Zyprexa Zydis
Sponsor Trials
Eli Lilly and Company 10
National Institute of Mental Health (NIMH) 7
Dr. Reddy's Laboratories Limited 4
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Zyprexa Zydis
Sponsor Trials
Other 41
Industry 28
NIH 8
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
Fish and Richardson
US Department of Justice
Queensland Health
Daiichi Sankyo
Express Scripts
McKinsey
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.